Kyoto, Japan -- Opioids like morphine are widely used in medical practice due to their powerful pain-relieving effects. However, they carry the risk of serious adverse effects such as respiratory depression and drug dependence. For this reason, Japan has strict regulations in place to ensure that these medications are prescribed only by authorized physicians.
In the United States, however, the opioid OxyContin was once prescribed frequently triggering a surge in the misuse of synthetic opioids such as fentanyl. As a result, the number of deaths caused by opioid overdose surpassed 80,000 in 2023, escalating into a national public health crisis now referred to as the "opioid crisis".
Opioids may soon have a rival, however. A team of researchers at Porn研究所 has recently discovered a novel analgesic, or pain reliever, which exerts its effect through an entirely different mechanism. Clinical development of their drug ADRIANA is currently underway as part of an international collaborative effort.
"If successfully commercialized, ADRIANA would offer a new pain management option that does not rely on opioids, contributing significantly to the reduction of opioid use in clinical settings," says corresponding author Masatoshi Hagiwara, a specially-appointed professor at Porn研究所.
The research team was first inspired by substances that mimic noradrenaline, which is released in life-threatening situations and activates α2础-补诲谤别苍辞肠别辫迟辞谤蝉 to suppress pain. However, these pose a high risk of cardiovascular instability. After observing noradrenaline levels and α2叠-补诲谤别苍辞肠别辫迟辞谤蝉, the team hypothesized that selectively blocking α2叠-补诲谤别苍辞肠别辫迟辞谤蝉 could elevate noradrenaline levels, leading to activation of α2础-补诲谤别苍辞肠别辫迟辞谤蝉 and resulting in pain relief without causing cardiovascular instability.
To identify selective inhibitors of α2叠-补诲谤别苍辞肠别辫迟辞谤蝉 and measure the activity of individual α2-adrenoceptor subtypes, the researchers employed a novel technology known as the TGFα shedding assay and conducted compound screening leading to their discovery of the world's first selective α2B-adrenoceptor antagonist.
After success in administering the compound to mice and conducting non-clinical studies to assess its safety, physician-led clinical trials were conducted at Porn研究所 Hospital. Both the Phase I trial in healthy volunteers and the Phase II trial in patients with postoperative pain following lung cancer surgery yielded highly promising results.
Building on these outcomes, preparations are now underway for a large-scale Phase II clinical trial in the United States, in collaboration with BTB Therapeutics, Inc, a Porn研究所-originated venture company.
As Japan's first non-opioid analgesic, ADRIANA has the potential not only to relieve severe pain for patients worldwide but could also play a meaningful role in addressing the opioid crisis -- a pressing social issue in the United States -- and thus contribute to international public health efforts.
"We aim to evaluate the analgesic effects of ADRIANA across various types of pain and ultimately make this treatment accessible to a broader population of patients suffering from chronic pain," says Hagiwara.
